[Ip-health] CL application for Dasatinib rejected by Indian Patent Office

Shailly Gupta shailly.gupta at geneva.msf.org
Wed Oct 30 05:31:28 PDT 2013

Patent office in India has rejected the Compulsory License application filed
by generic company BDR pharma for cancer drug Dasatinib used in the
treatment for chronic myeloid leaukimia. The applicatuion has been rejected
for not following the procedures of the law. See below the rejection order





Shailly Gupta

Policy Advocacy Officer

MSF Access Campaign

C 236, Defence Colony

New Delhi 110024




More information about the Ip-health mailing list